Credit Suisse’s NeoGenomics NEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $4.08M | Buy |
259,253
+3,386
| +1% | +$52.3K | ﹤0.01% | 1409 |
|
|
2023
Q4 | $4.14M | Buy |
255,867
+48,568
| +23% | +$795K | ﹤0.01% | 1443 |
|
|
2023
Q3 | $2.56M | Sell |
207,299
-8,060
| -4% | -$120K | ﹤0.01% | 1676 |
|
|
2023
Q2 | $3.46M | Buy |
215,359
+31,528
| +17% | +$520K | ﹤0.01% | 1575 |
|
|
2023
Q1 | $3.2M | Buy |
183,831
+34,852
| +23% | +$496K | ﹤0.01% | 1596 |
|
|
2022
Q4 | $1.38M | Buy |
148,979
+25,483
| +21% | +$238K | ﹤0.01% | 2119 |
|
|
2022
Q3 | $1.06M | Sell |
123,496
-387,950
| -76% | -$3.85M | ﹤0.01% | 2287 |
|
|
2022
Q2 | $4.17M | Buy |
511,446
+388,087
| +315% | +$3.71M | ﹤0.01% | 1408 |
|
|
2022
Q1 | $1.5M | Buy |
123,359
+15,328
| +14% | +$323K | ﹤0.01% | 2274 |
|
|
2021
Q4 | $3.69M | Sell |
108,031
-1,497
| -1% | -$58.6K | ﹤0.01% | 2281 |
|
|
2021
Q3 | $5.28M | Sell |
109,528
-50,307
| -31% | -$2.33M | ﹤0.01% | 2019 |
|
|
2021
Q2 | $7.22M | Buy |
159,835
+25,563
| +19% | +$1.13M | ﹤0.01% | 1783 |
|
|
2021
Q1 | $6.48M | Sell |
134,272
-1,745
| -1% | -$90.8K | ﹤0.01% | 1863 |
|
|
2020
Q4 | $7.32M | Sell |
136,017
-11,532
| -8% | -$521K | ﹤0.01% | 1790 |
|
|
2020
Q3 | $5.44M | Buy |
147,549
+22,086
| +18% | +$821K | ﹤0.01% | 1751 |
|
|
2020
Q2 | $3.89M | Buy |
125,463
+31,564
| +34% | +$875K | ﹤0.01% | 1879 |
|
|
2020
Q1 | $2.59M | Sell |
93,899
-12,776
| -12% | -$383K | ﹤0.01% | 1957 |
|
|
2019
Q4 | $3.12M | Buy |
106,675
+10,507
| +11% | +$250K | ﹤0.01% | 2250 |
|
|
2019
Q3 | $1.84M | Sell |
96,168
-10,622
| -10% | -$249K | ﹤0.01% | 2529 |
|
|
2019
Q2 | $2.34M | Buy |
106,790
+11,779
| +12% | +$258K | ﹤0.01% | 2344 |
|
|
2019
Q1 | $1.94M | Sell |
95,011
-977
| -1% | -$17K | ﹤0.01% | 2393 |
|
|
2018
Q4 | $1.21M | Buy |
95,988
+38,098
| +66% | +$568K | ﹤0.01% | 2633 |
|
|
2018
Q3 | $888K | Sell |
57,890
-17,886
| -24% | -$247K | ﹤0.01% | 2947 |
|
|
2018
Q2 | $994K | Sell |
75,776
-12,130
| -14% | -$133K | ﹤0.01% | 3016 |
|
|
2018
Q1 | $717K | Buy |
87,906
+11,572
| +15% | +$93.8K | ﹤0.01% | 3170 |
|
|
2017
Q4 | $677K | Buy |
76,334
+10,278
| +16% | +$94.8K | ﹤0.01% | 3261 |
|
|
2017
Q3 | $736K | Buy |
66,056
+33,289
| +102% | +$324K | ﹤0.01% | 3301 |
|
|
2017
Q2 | $294K | Sell |
32,767
-13,415
| -29% | -$106K | ﹤0.01% | 3466 |
|
|
2017
Q1 | $364K | Sell |
46,182
-15,915
| -26% | -$130K | ﹤0.01% | 3454 |
|
|
2016
Q4 | $533K | Buy |
62,097
+37
| +0.1% | +$317 | ﹤0.01% | 3409 |
|
|
2016
Q3 | $511K | Sell |
62,060
-59,836
| -49% | -$502K | ﹤0.01% | 3403 |
|
|
2016
Q2 | $980K | Buy |
+121,896
| New | +$977K | ﹤0.01% | 2937 |
|
|
2016
Q1 | – | Sell |
-17,627
| Closed | -$139K | – | 4191 |
|
|
2015
Q4 | $139K | Sell |
17,627
-4,617
| -21% | -$33.8K | ﹤0.01% | 4017 |
|
|
2015
Q3 | $127K | Sell |
22,244
-1,976
| -8% | -$12.2K | ﹤0.01% | 4064 |
|
|
2015
Q2 | $131K | Sell |
24,220
-101,152
| -81% | -$522K | ﹤0.01% | 4336 |
|
|
2015
Q1 | $586K | Buy |
125,372
+34,838
| +38% | +$151K | ﹤0.01% | 3433 |
|
|
2014
Q4 | $378K | Buy |
90,534
+54,356
| +150% | +$250K | ﹤0.01% | 3908 |
|
|
2014
Q3 | $188K | Sell |
36,178
-33,588
| -48% | -$173K | ﹤0.01% | 4154 |
|
|
2014
Q2 | $231K | Buy |
69,766
+42,870
| +159% | +$142K | ﹤0.01% | 4271 |
|
|
2014
Q1 | $93K | Sell |
26,896
-2,336
| -8% | -$8.75K | ﹤0.01% | 4523 |
|
|
2013
Q4 | $105K | Buy |
29,232
+13,298
| +83% | +$46.2K | ﹤0.01% | 4460 |
|
|
2013
Q3 | $48K | Sell |
15,934
-38
| -0.2% | -$107 | ﹤0.01% | 4151 |
|
|
2013
Q2 | $64K | Buy |
+15,972
| New | +$60.9K | ﹤0.01% | 4082 |
|
Other funds holding NEO
GF
FLAM
Credit Suisse's NEO Position: Q1 2024 in Review
Credit Suisse increased its NeoGenomics (NEO) stake by 1.3% in Q1 2024, buying an estimated $52.3K and bringing the position to 259,253 shares worth $4.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1409.
Credit Suisse first reported a position in NEO in Q2 2013 and has held it in 43 quarters since. The position peaked at $7.32M in Q4 2020. 263 funds tracked by Wall St. Rank hold NEO as of Q1 2024.
- Credit Suisse held 259,253 shares of NeoGenomics worth $4.08M as of Q1 2024.
- Credit Suisse bought 3,386 NeoGenomics shares in Q1 2024, an estimated $52.3K.
- NeoGenomics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1409 holding.
- Credit Suisse first reported a position in NeoGenomics in Q2 2013 and has held it in 43 quarters since.
- Credit Suisse's NeoGenomics position peaked at $7.32M in Q4 2020.
- 263 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.